메뉴 건너뛰기




Volumn 21, Issue 11, 2016, Pages 1306-1314

Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer

Author keywords

Biomarker; Cetuximab; Colon cancer; Epidermal growth factor receptor; Genomic profiling; KRAS

Indexed keywords

CD135 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; SCATTER FACTOR RECEPTOR;

EID: 84995467027     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0148     Document Type: Article
Times cited : (35)

References (58)
  • 3
    • 84953856186 scopus 로고    scopus 로고
    • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the openlabel, phase 3 TRIBE study
    • Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the openlabel, phase 3 TRIBE study. Lancet Oncol 2015;16: 1306-1315.
    • (2015) Lancet Oncol , vol.16 , pp. 1306-1315
    • Cremolini, C.1    Loupakis, F.2    Antoniotti, C.3
  • 4
    • 84920954757 scopus 로고    scopus 로고
    • FOLFOXIRI and bevacizumab formetastatic colorectal cancer
    • Cremolini C, Loupakis F, Falcone A. FOLFOXIRI and bevacizumab formetastatic colorectal cancer. N Engl JMed 2015;372:291-292.
    • (2015) N Engl Jmed , vol.372 , pp. 291-292
    • Cremolini, C.1    Loupakis, F.2    Falcone, A.3
  • 5
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumabas first-line treatment for patientswithmetastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
    • Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumabas first-line treatment for patientswithmetastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-1075.
    • (2014) Lancet Oncol , vol.15 , pp. 1065-1075
    • Heinemann, V.1    Von Weikersthal, L.F.2    Decker, T.3
  • 6
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369: 1023-1034.
    • (2013) N Engl J Med , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1    Oliner, K.S.2    Siena, S.3
  • 7
    • 84903694472 scopus 로고    scopus 로고
    • Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
    • Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25: 1346-1355.
    • (2014) Ann Oncol , vol.25 , pp. 1346-1355
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3
  • 8
    • 57449095367 scopus 로고    scopus 로고
    • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
    • (2008) J Clin Oncol , vol.26 , pp. 5705-5712
    • Di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 9
    • 79956298812 scopus 로고    scopus 로고
    • Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    • Van Cutsem E, Köhne C-H, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
    • (2011) J Clin Oncol , vol.29 , pp. 2011-2019
    • van Cutsem, E.1    Köhne, C.-H.2    Láng, I.3
  • 10
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl JMed 2008;359: 1757-1765.
    • (2008) N Engl Jmed , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 11
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
    • Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011; 22:1535-1546.
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 12
    • 84908431348 scopus 로고    scopus 로고
    • Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
    • Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-1280.
    • (2014) Cancer Discov , vol.4 , pp. 1269-1280
    • Misale, S.1    Di Nicolantonio, F.2    Sartore-Bianchi, A.3
  • 13
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • De Roock W, De Vriendt V, Normanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
    • (2011) Lancet Oncol , vol.12 , pp. 594-603
    • de Roock, W.1    de Vriendt, V.2    Normanno, N.3
  • 14
    • 77955046517 scopus 로고    scopus 로고
    • Genomic and biological characterization of exon 4 KRA Smutations in human cancer
    • Janakiraman M, Vakiani E, Zeng Z et al. Genomic and biological characterization of exon 4 KRA Smutations in human cancer. Cancer Res 2010; 70:5901-5911.
    • (2010) Cancer Res , vol.70 , pp. 5901-5911
    • Janakiraman, M.1    Vakiani, E.2    Zeng, Z.3
  • 15
    • 84964314170 scopus 로고    scopus 로고
    • Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
    • Morris VK, Lucas FAS, Overman MJ et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 2014;25: 2008-2014.
    • (2014) Ann Oncol , vol.25 , pp. 2008-2014
    • Morris, V.K.1    Lucas, F.2    Overman, M.J.3
  • 16
    • 68749119351 scopus 로고    scopus 로고
    • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer
    • Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer. Br J Cancer 2009;101:715-721.
    • (2009) Br J Cancer , vol.101 , pp. 715-721
    • Loupakis, F.1    Ruzzo, A.2    Cremolini, C.3
  • 17
    • 84995461857 scopus 로고    scopus 로고
    • Accessed June 8, 2016
    • NCCN Guidelines v.3.2015. Available at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 8, 2016.
  • 18
    • 84942868219 scopus 로고    scopus 로고
    • Molecular pathways: Sensitivity and resistance to anti-EGFR antibodies
    • Bertotti A, Sassi F. Molecular pathways: Sensitivity and resistance to anti-EGFR antibodies. Clin Cancer Res 2015;21:3377-3383.
    • (2015) Clin Cancer Res , vol.21 , pp. 3377-3383
    • Bertotti, A.1    Sassi, F.2
  • 19
    • 84936748494 scopus 로고    scopus 로고
    • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
    • Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21:795-801.
    • (2015) Nat Med , vol.21 , pp. 795-801
    • Siravegna, G.1    Mussolin, B.2    Buscarino, M.3
  • 20
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • de Roock, W.1    Claes, B.2    Bernasconi, D.3
  • 21
    • 59049089201 scopus 로고    scopus 로고
    • PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab inmetastatic colorectal cancer patients
    • Perrone F, Lampis A, Orsenigo M et al. PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab inmetastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
    • (2009) Ann Oncol , vol.20 , pp. 84-90
    • Perrone, F.1    Lampis, A.2    Orsenigo, M.3
  • 22
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
    • (2012) Nature , vol.487 , pp. 330-337
  • 23
    • 84944079826 scopus 로고    scopus 로고
    • The genomic landscape of response to EGFR blockade in colorectal cancer
    • Bertotti A, Papp E, Jones S et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-267.
    • (2015) Nature , vol.526 , pp. 263-267
    • Bertotti, A.1    Papp, E.2    Jones, S.3
  • 24
    • 84887491073 scopus 로고    scopus 로고
    • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
    • Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
    • (2013) Nat Biotechnol , vol.31 , pp. 1023-1031
    • Frampton, G.M.1    Fichtenholtz, A.2    Otto, G.A.3
  • 25
    • 84995509582 scopus 로고    scopus 로고
    • Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP)
    • Hall MJ, Gowen K, Sanford E M et al. Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). J Clin Oncol 2016; 34(suppl 4S):528a.
    • (2016) J Clin Oncol , vol.34 , pp. 528
    • Hall, M.J.1    Gowen, K.2    Sanford, E.M.3
  • 26
    • 12144289677 scopus 로고    scopus 로고
    • Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    • Wan PTC, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116: 855-867.
    • (2004) Cell , vol.116 , pp. 855-867
    • Wan, P.1    Garnett, M.J.2    Roe, S.M.3
  • 27
    • 84879240684 scopus 로고    scopus 로고
    • KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
    • Valtorta E, Misale S, Sartore-Bianchi A et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-1265.
    • (2013) Int J Cancer , vol.133 , pp. 1259-1265
    • Valtorta, E.1    Misale, S.2    Sartore-Bianchi, A.3
  • 28
    • 79958796709 scopus 로고    scopus 로고
    • Biomarker-based selection of therapy for colorectal cancer
    • Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomarkers Med 2011;5: 319-332.
    • (2011) Biomarkers Med , vol.5 , pp. 319-332
    • Ross, J.S.1
  • 29
    • 84932606172 scopus 로고    scopus 로고
    • Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
    • Arena S, Bellosillo B, Siravegna G et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015;21:2157-2166.
    • (2015) Clin Cancer Res , vol.21 , pp. 2157-2166
    • Arena, S.1    Bellosillo, B.2    Siravegna, G.3
  • 30
    • 84931364786 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
    • Braig F, März M, Schieferdecker A et al. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 2015;6: 12035-12047.
    • (2015) Oncotarget , vol.6 , pp. 12035-12047
    • Braig, F.1    März, M.2    Schieferdecker, A.3
  • 31
    • 84856717005 scopus 로고    scopus 로고
    • Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer [published correction appears in Nat Med 2012;18:1445]
    • Montagut C, Dalmases A, Bellosillo B et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer [published correction appears in Nat Med 2012;18:1445]. Nat Med 2012;18:221-223.
    • (2012) Nat Med , vol.18 , pp. 221-223
    • Montagut, C.1    Dalmases, A.2    Bellosillo, B.3
  • 32
    • 84878862323 scopus 로고    scopus 로고
    • Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
    • Bardelli A, Corso S, Bertotti A et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-673.
    • (2013) Cancer Discov , vol.3 , pp. 658-673
    • Bardelli, A.1    Corso, S.2    Bertotti, A.3
  • 33
    • 80052591747 scopus 로고    scopus 로고
    • Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
    • Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
    • (2011) Sci Transl Med , vol.3
    • Yonesaka, K.1    Zejnullahu, K.2    Okamoto, I.3
  • 34
    • 84939181687 scopus 로고    scopus 로고
    • HER2activating mutations are targets for colorectal cancer treatment
    • Kavuri SM, Jain N, Galimi F et al. HER2activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5:832-841.
    • (2015) Cancer Discov , vol.5 , pp. 832-841
    • Kavuri, S.M.1    Jain, N.2    Galimi, F.3
  • 35
    • 84933040790 scopus 로고    scopus 로고
    • Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer throughMAPK pathway alterations
    • Ahronian LG, Sennott EM, Van Allen EM et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer throughMAPK pathway alterations. Cancer Discov 2015;5:358-367.
    • (2015) Cancer Discov , vol.5 , pp. 358-367
    • Ahronian, L.G.1    Sennott, E.M.2    van Allen, E.M.3
  • 36
    • 84903301924 scopus 로고    scopus 로고
    • The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
    • Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852-864.
    • (2014) Acta Oncol , vol.53 , pp. 852-864
    • Therkildsen, C.1    Bergmann, T.K.2    Henrichsen-Schnack, T.3
  • 37
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies
    • Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res 2009; 69:1851-1857.
    • (2009) Cancer Res , vol.69 , pp. 1851-1857
    • Sartore-Bianchi, A.1    Martini, M.2    Molinari, F.3
  • 38
    • 73349094741 scopus 로고    scopus 로고
    • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer
    • Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-5930.
    • (2009) J Clin Oncol , vol.27 , pp. 5924-5930
    • Laurent-Puig, P.1    Cayre, A.2    Manceau, G.3
  • 39
    • 84962298279 scopus 로고    scopus 로고
    • Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF
    • Hechtman JF, Zehir A, Yaeger R et al. Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF. Mol Cancer Res 2016;14:296-301.
    • (2016) Mol Cancer Res , vol.14 , pp. 296-301
    • Hechtman, J.F.1    Zehir, A.2    Yaeger, R.3
  • 40
    • 84958551355 scopus 로고    scopus 로고
    • Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
    • Disel U, Germain A, Yilmazel B et al. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience 2015; 2:581-584.
    • (2015) Oncoscience , vol.2 , pp. 581-584
    • Disel, U.1    Germain, A.2    Yilmazel, B.3
  • 41
    • 84995437954 scopus 로고    scopus 로고
    • Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors
    • Hurwitz H, Hainsworth JD, Swanton C et al. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. J Clin Oncol 2016;34(suppl 4S):653a.
    • (2016) J Clin Oncol , vol.34 , pp. 653
    • Hurwitz, H.1    Hainsworth, J.D.2    Swanton, C.3
  • 42
    • 84929575728 scopus 로고    scopus 로고
    • Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification
    • Moreira RB, Peixoto RD, de Sousa Cruz MR. Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification. Case Rep Oncol 2015;8:83-87.
    • (2015) Case Rep Oncol , vol.8 , pp. 83-87
    • Moreira, R.B.1    Peixoto, R.D.2    de Sousa Cruz, M.R.3
  • 43
    • 84957063275 scopus 로고    scopus 로고
    • Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
    • Russo M, Siravegna G, Blaszkowsky LS et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 2016;6:147-153.
    • (2016) Cancer Discov , vol.6 , pp. 147-153
    • Russo, M.1    Siravegna, G.2    Blaszkowsky, L.S.3
  • 44
    • 85011961061 scopus 로고    scopus 로고
    • BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy
    • Klempner SJ, Gershenhorn B, Tran P et al. BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov 2016;6:594-600.
    • (2016) Cancer Discov , vol.6 , pp. 594-600
    • Klempner, S.J.1    Gershenhorn, B.2    Tran, P.3
  • 45
    • 84958078144 scopus 로고    scopus 로고
    • MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
    • Arena S, Siravegna G, Mussolin B et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 2016;8:324ra14.
    • (2016) Sci Transl Med , vol.8
    • Arena, S.1    Siravegna, G.2    Mussolin, B.3
  • 46
    • 84979992202 scopus 로고    scopus 로고
    • Oncogenic ALK Fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target
    • Yakirevich E, Resnick MB, Mangray S et al. Oncogenic ALK Fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res 2016;22:3831-3840.
    • (2016) Clin Cancer Res , vol.22 , pp. 3831-3840
    • Yakirevich, E.1    Resnick, M.B.2    Mangray, S.3
  • 47
    • 84954060726 scopus 로고    scopus 로고
    • Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
    • Russo M, Misale S, Wei G et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 2016;6:36-44.
    • (2016) Cancer Discov , vol.6 , pp. 36-44
    • Russo, M.1    Misale, S.2    Wei, G.3
  • 48
    • 84945152069 scopus 로고    scopus 로고
    • Identification and characterization of RET fusions in advanced colorectal cancer
    • Le Rolle A-F, Klempner SJ, Garrett CR et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015;6: 28929-28937.
    • (2015) Oncotarget , vol.6 , pp. 28929-28937
    • Le Rolle, A.-F.1    Klempner, S.J.2    Garrett, C.R.3
  • 49
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
    • (2015) N Engl J Med , vol.372 , pp. 2509-2520
    • Le, D.T.1    Uram, J.N.2    Wang, H.3
  • 50
    • 77449130761 scopus 로고    scopus 로고
    • Microsatellite instability in colorectal cancer
    • Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138: 2073-2087.e3.
    • Gastroenterology 2010 , vol.138 , pp. 2073-2087
    • Boland, C.R.1    Goel, A.2
  • 51
    • 84973622902 scopus 로고    scopus 로고
    • Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in nextgeneration sequencing panels
    • Stadler ZK, Battaglin F, Middha S et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in nextgeneration sequencing panels. J Clin Oncol 2016;34: 2141-2147.
    • (2016) J Clin Oncol , vol.34 , pp. 2141-2147
    • Stadler, Z.K.1    Battaglin, F.2    Middha, S.3
  • 52
    • 84954202031 scopus 로고    scopus 로고
    • Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015
    • Allegra CJ, Rumble RB, Hamilton SR et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 2016;34:179-185.
    • (2016) J Clin Oncol , vol.34 , pp. 179-185
    • Allegra, C.J.1    Rumble, R.B.2    Hamilton, S.R.3
  • 53
    • 12644273250 scopus 로고    scopus 로고
    • Biochemical characterization of a novel KRAS insertion mutation from a human leukemia
    • Bollag G, Adler F, elMasry N et al. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 1996;271:32491-32494.
    • (1996) J Biol Chem , vol.271 , pp. 32491-32494
    • Bollag, G.1    Adler, F.2    Elmasry, N.3
  • 54
    • 84901710704 scopus 로고    scopus 로고
    • Characterization of rare transforming KRAS mutations in sporadic colorectal cancer
    • Tong JHM, Lung RWM, Sin FMC et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15:768-776.
    • (2014) Cancer Biol Ther , vol.15 , pp. 768-776
    • Tong, J.1    Lung, R.2    Sin, F.3
  • 55
    • 84896118508 scopus 로고    scopus 로고
    • KRAS insertions in colorectal cancer: What do we know about unusual KRAS mutations?
    • de Macedo MP, de Lima LGCA, Begnami MDFS et al. KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? Exp Mol Pathol 2014;96:257-260.
    • (2014) Exp Mol Pathol , vol.96 , pp. 257-260
    • de Macedo, M.P.1    de Lima, L.2    Begnami, M.3
  • 56
    • 47749128875 scopus 로고    scopus 로고
    • KRAS mutation profile in colorectal carcinoma and novelmutation-internal tandem duplication in KRAS
    • Wójcik P, Kulig J, Okón K et al. KRAS mutation profile in colorectal carcinoma and novelmutation-internal tandem duplication in KRAS. Pol J Pathol 2008;59:93-96.
    • (2008) Pol J Pathol , vol.59 , pp. 93-96
    • Wójcik, P.1    Kulig, J.2    Okón, K.3
  • 57
    • 84877130883 scopus 로고    scopus 로고
    • Effect of low-frequency KRASmutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    • Tougeron D, Lecomte T, Pagès JC et al. Effect of low-frequency KRASmutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013;24:1267-1273.
    • (2013) Ann Oncol , vol.24 , pp. 1267-1273
    • Tougeron, D.1    Lecomte, T.2    Pagès, J.C.3
  • 58
    • 84895060068 scopus 로고    scopus 로고
    • KRAS testing in metastatic colorectal carcinoma: Challenges, controversies, breakthroughs and beyond
    • Malapelle U, Carlomagno C, de Luca C et al. KRAS testing in metastatic colorectal carcinoma: Challenges, controversies, breakthroughs and beyond. J Clin Pathol 2014;67:1-9.
    • (2014) J Clin Pathol , vol.67 , pp. 1-9
    • Malapelle, U.1    Carlomagno, C.2    de Luca, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.